The peptidic middle molecules: is molecular weight doing the trick?

Area of Science:

• Nephrology
• Cardiology
• Toxicology

Background:

• Chronic kidney disease (CKD) is marked by progressive endogenous intoxication.
• Uremic toxicity from accumulating compounds contributes to cardiovascular disease and mortality in CKD.
• Peptidic middle molecules are a significant class of uremic toxins.

Purpose of the Study:

• To review main peptidic middle molecules in CKD.
• To explore their role in cardiometabolic complications.
• To highlight challenges in their removal via dialysis.

Main Methods:

• Literature review of peptidic middle molecules.
• Analysis of their molecular characteristics (500-60,000 Da).
• Examination of their association with CKD-related cardiometabolic issues.

Main Results:

• Identified key peptidic middle molecules implicated in uremic toxicity.
• Established their link to cardiovascular complications in CKD.
• Highlighted difficulty in removing these molecules with standard dialysis.

Conclusions:

• Peptidic middle molecules are major contributors to cardiometabolic complications in CKD.
• Effective removal strategies for these toxins are needed.
• Further research into these molecules is crucial for CKD patient outcomes.